Abstract
Small interfering RNAs (siRNAs) have been widely used for knocking down gene expression in a variety of organisms. Although experiments in cancer cell lines indicate that siRNAs are usually not detected by innate immunity, lipid-mediated delivery of siRNAs into blood cells is often accompanied by the activation of immunity. Recent studies indicated that certain siRNA sequences engage Toll-like receptor TLR7/8 signalling resulting in the activation of a large number of host defense genes including interferons (IFNs), proinflammatory cytokines, Mx proteins, chemokines, chemokine receptors, costimulatory molecules, RNA helicases, galectins, and ubiqitin ligases. In addition to immune activation, most siRNA sequences, if not all, can silence multiple genes in addition to the intended target gene, a phenomenon known as “off-target effects.” Hence, one of the major challenges for therapeutic applications of siRNAs is to decipher the mechanisms involved in siRNA recognition by the immune system and to identify strategies that can evade immune activation. In this respect, the replacement of only uridines with their 2′-modified counterparts such as 2′-O-methyl uridines abrogate immune recognition of siRNAs. Interestingly, 2′-O-methyl-modified RNAs not only evade TLR7/8-sensing pathways, but also reduce siRNA off-target effects and antagonize with a variety of immunostimulatory RNAs to activate TLR7/8 signalling. RNA oligonucleotides and duplex siRNAs with 2’-deoxy uridines or thymidines exhibited no significant immunostimulatory effects and binding potency to TLRs. Therefore, I recommend the use of these modifications in order to evade immune sensing of siRNA and off-target effects. This chapter addresses the current state of knowledge regarding the molecular and cellular mechanisms of RNA recognition by the immune system and proposes a range of strategies allowing the design of siRNAs with minimal or maximal immunostimulatory potency for therapeutic applications.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Jorgensen, R. (1990) Altered gene expression in plants due to trans interactions between homologous genes. Trends Biotechnol, 8, 340–344.
Fire, A., Xu, S., Montgomery, M. K., et al. (1998) Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature, 391, 806–811.
Svoboda, P., Stein, P., Hayashi, H., et al. (2000) Selective reduction of dormant maternal mRNAs in mouse oocytes by RNA interference. Development, 127, 4147–4156.
Sen, G. C. (2001) Viruses and interferons. Annu Rev Microbiol, 55, 255–281.
Zamore, P. D., Tuschl, T., Sharp, P. A., et al. (2000) RNAi: double-stranded RNA directs the ATP-dependent cleavage of mRNA at 21 to 23 nucleotide intervals. Cell, 101, 25–33.
Elbashir, S. M., Lendeckel, W., and Tuschl, T. (2001) RNA interference is mediated by 21- and 22-nucleotide RNAs. Genes Dev, 15, 188–200.
Elbashir, S. M., Harborth, J., Lendeckel, W., et al. (2001) Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature, 411, 494–498
Sioud, M. (2004) Therapeutic siRNAs. Trends Pharmacol Sci, 25, 22–28.
Hannon, G. J. and Rossi, J. J. (2004) Unlocking the potential of the human genome with RNA interference. Nature, 431, 371–378
Liu, J., Carmell, M. A., Rivas, F. V., et al. (2004) Argonaute2 is the catalytic engine of mammalian RNAi. Science, 305, 1437–1441.
Song, J. J., Smith, S. K., Hannon, G. J., et al. (2004) Crystal structure of Argonaute and its implications for RISC slicer activity. Science, 305, 1434–147.
Matranga, C., Tomari, Y., Shin, C., et al. (2005) Passenger-strand cleavage facilitates assembly of siRNA into Ago2-containing RNAi enzyme complexes. Cell, 123, 607–620.
Rand, T. A., Petersen, S., Du, F., et al. (2005) Wang: Argonaute2 cleaves the anti-guide strand of siRNA during RISC activation. Cell, 123, 621–629.
Ma, J. B., Yuan, Y. R., Meister, G., et al. (2005) Structural basis for 5′-end-specific recognition of guide RNA by the A. fulgidus. Piwi protein Nature, 434, 666–670.
Sioud, M. and Sorensen, D. R. (2003) Cationic liposome-mediated delivery of siRNAs in adult mice. Biochem Biophys Res Commun, 312, 1220–1225.
Jackson, A. L., Bartz, S. R., Schelter, J., et al. (2003) Expression profiling reveals off-target gene regulation by RNAi. Nat Biotechnol, 21, 635–637.
Semizarov, D., Frost, L., Sarthy, A., et al. (2003) Specificity of short interfering RNA determined through gene expression signatures. Proc Natl Acad Sci U S A, 100, 6347–6352.
Sledz, C. A., Holko, M., de Veer, M. J., et al. (2003) Activation of the interferon system by short-interfering RNAs. Nat Cell Biol, 5, 834–839.
Parkin, J. and Cohen, B. (2001) An overview of the immune system. Lancet, 357, 1777–1789.
Janeway, C. A. and Medzhitov, R. Jr. (2002) Innate immune recognition. Annu Rev Immunol, 20, 197–216.
Takeda, K. and Akira, S. (2005) Toll-like receptors in innate immunity. Int Immunol, 17, 1–14.
Sioud, M. (2006) Innate sensing of self and non-self RNAs by Toll-like receptors. Trends Mol Med, 12, 167–716.
Brennan, C. A. and Anderson, K. V. (2004) Drosophila: The genetics of innate immune recognition and response. Annu Rev Immunol, 22, 457–483.
Lemaitre, B., Nicolas, E., Michaut, L., et al. (1996) The dorsoventral regulatory gene cassette spatzle/Toll/cactus controls the potent antifungal response in Drosophila adults. Cell, 86, 973–983.
Akira, S. and Takeda, K. (2004) Toll-like receptor signaling. Nat Rev Immunol, 4, 499–511.
Li, S., Peters, G. A., Ding, K., et al. (2006) Molecular basis for PKR activation by PACT or dsRNA. Proc Natl Acad Sci U S A, 103, 10005–10010.
Samuel, C. E. (2001) Antiviral actions of interferons. Clin Microbiol Rev, 14, 778–809.
Kato, H., Takeuchi, O., Sato, S., et al. (2006) Differential roles of MDA5 and RIG-I helicases in the recognition of RNA viruses. Nature, 441, 101–105.
Meylan, E., Tschopp, J., and Karin, M. (2006) Intracellular pattern recognition receptors in the host response. Nature, 442, 39–44.
Alexopoulou, L., Holt, A. C., Medzhitov, R., and Flavell, R. A. (2001) Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3. Nature, 413, 732–438.
Heil, F., Hemmi, H., Hochrein, H., et al. (2004) Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8. Science, 303, 1526–1529.
Krieg, A. M. (2002) CpG motifs in bacterial DNA and their immune effects. Annu Rev Immunol, 20, 709–760
Brentano, F., Kyburz, D., Schorr, O., et al. (2005) The role of Toll-like receptor signaling in the pathogenesis of arthritis. Cell Immunol, 233, 90–96.
Cao, W. and Liu, Y. J. (2007) Innate immune functions of plasmacytoid dendritic cells. Curr Opin Immunol, 19, 24–30.
Sioud, M. (2005) Induction of inflammatory cytokines and interferon responses by double-stranded and single-stranded siRNAs is sequence-dependent and requires endosomal localization. J Mol Biol, 348, 1079–1090
Hornung, V., Guenthner-Biller, M., Bourquin, C., et al. (2005) Sequence-specific potent induction of IFN-alpha by short interfering RNA in plasmacytoid dendritic cells through TLR7. Nat Med, 11, 263–270.
Judge, A. D., Sood, V., Shaw, J. R., et al. (2005) Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA. Nat Biotechnol, 23, 457–462.
Sioud, M. (2006) Single-stranded small interfering RNA are more immunostimulatory than their double-stranded counterparts: a central role for 2′-hydroxyl uridines in immune responses. Eur J Immunol, 36, 1222–1230.
Kariko, K., Bhuyan, P., Capodici, J., et al. (2004) Small interfering RNAs mediate sequence-independent gene suppression and induce immune activation by signaling through toll-like receptor 3. J Immunol, 172, 6545–6549.
Cekaite, L., Furset, G., Hovig, E., et al. (2007) Gene expression analysis in blood cells in response to unmodified and 2′-modified siRNAs reveals TLR-dependent and independent effects. J Mol Biol, 365, 90–108.
Morrissey, D. V., Lockridge, J. A., Shaw, L., et al. (2005) Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs. Nat Biotechnol, 23, 1002–1007.
Judge, A. D., Bola, G., Lee, A. C., et al. (2006) Design of noninflammatory synthetic siRNA mediating potent gene silencing in vivo. Mol Ther, 13, 494–505.
Kariko, K., Buckstein, M., Ni, H., et al. (2005) Suppression of RNA recognition by Toll-like receptors: The impact of nucleoside modification and the evolutionary origin of RNA. Immunity, 23, 165–175.
Sioud, M. (2007) RNA interference and innate immunity. Adv Drug Deliv Rev, 59, 153–163.
Sioud, M., Furset, G., and Cekaite, L. (2007) Suppression of immunostimulatory siRNA-driven innate immune activation by 2′-modified RNAs. Biochem Biophys Res Commun, 361, 122–126.
. Furset, G., Floisand, Y., and Sioud, M. (2008) Impaired expression of indoleamine 2, 3-dioxygenase in monocyte-derived dendritic cells in response to Toll-like receptor-7/8 ligands. Immunology,123, 263-71.
Robbins, M., Judge, A., Liang, L., et al. (2007) 2′-O. -methyl-modified RNAs act as TLR7 antagonists Mol Ther, 15, 1663–1669.
Marques, J. T., Devosse, T., Wang, D., et al. (2006) A structural basis for discriminating between self and nonself double-stranded RNAs in mammalian cells. Nat Biotechnol, 24, 559–565.
Robbins, M. A., Li, M., Leung, I., et al. (2006) Stable expression of shRNAs in human CD34 + progenitor cells can avoid induction of interferon responses to siRNAs in vitro. Nat Biotechnol, 24, 566–571.
Sioud, M. (2006) RNA interference below the immune radar. Nat Biotechnol, 24, 521–522
Bartel, D. P. (2004) MicroRNAs: genomics, biogenesis, mechanism, and function. Cell, 116, 281–297.
Han, J., Lee, Y., Yeom, K. H., et al. (2006) Molecular basis for the recognition of primary microRNAs by the Drosha-DGCR8 complex. Cell, 125, 887–901.
Furset, G. and Sioud, M. (2007) Design of bifunctional siRNAs combining immunostimulation and gene-silencing in one single siRNA molecule. Biochem Biophys Res Commun, 352, 642–649.
Hornung, V., Ellegast, J., Kim, S., et al. (2006) 5′-Triphosphate RNA is the ligand for RIG-I. Science, 314, 994–997.
Jackson, A. L., Burchard, J., Leake, D., et al. (2006) Position-specific chemical modification of siRNAs reduces “off-target” transcript silencing. RNA, 12, 1197–205.
Banchereau, J. and Steinman, R. M. (1998) Dendritic cells and the control of immunity. Nature, 392, 245–252.
Rossi, M. and Young, J. W. (2005) Human dendritic cells: Potent antigen-presenting cells at the crossroads of innate and adaptive immunity. J Immunol, 175, 1373–1381.
Pardoll, D. (2003) Does the immune system see tumors as foreign or self? Annu Rev Immunol, 21, 807–839.
Grutz, G. (2005) New insights into the molecular mechanism of interleukin-10-mediated immunosuppression. J Leukoc Biol, 77, 3–15.
Alexander, W. S. and Hilton, D. J. (2004) The role of suppressors of cytokine signaling (SOCS) proteins in regulation of the immune response. Annu Rev Immunol, 22, 503–529.
Shen, L., Evel-Kabler, K., Strube, R., et al. (2004) Silencing of SOCS1 enhances antigen presentation by dendritic cells and antigen-specific anti-tumor immunity. Nat Biotechnol, 22, 1546–1553.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2009 Humana Press, a part of Springer Science+Business Media, LLC
About this protocol
Cite this protocol
Sioud , M. (2009). Deciphering the Code of Innate Immunity Recognition of siRNAs. In: Sioud, M. (eds) siRNA and miRNA Gene Silencing. Methods in Molecular Biology, vol 487. Humana Press. https://doi.org/10.1007/978-1-60327-547-7_2
Download citation
DOI: https://doi.org/10.1007/978-1-60327-547-7_2
Published:
Publisher Name: Humana Press
Print ISBN: 978-1-60327-546-0
Online ISBN: 978-1-60327-547-7
eBook Packages: Springer Protocols